Across TCGA pan-cancer cohorts, RPL32P17 RNA differs between tumor and matched normal tissue in 2 of 18 cancer types tested, making tumor–normal expression one of RPL32P17’s most consistent transcriptional readouts.

The strongest signal is observed in pancreatic adenocarcinoma (PAAD), where RPL32P17 RNA is repressed in tumor relative to normal tissue. In most cancer types RPL32P17 is over-expressed in tumor, although a few such as PAAD show the opposite, repressed pattern.

PAAD and KIRC are the cancer types where RPL32P17 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RPL32P17 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
PAAD	All	All	−0.217	.043	2	view →
KIRC	All	All	+0.027	.019	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 2 strongest of 2 lineages.

Exploration

Same gene, other analysis: RPL32P17 RNA expression & survival · all RPL32P17 data types